3,3'-Diindolylmethane (DIM)
SupplementThe medical evidence (score 52) is limited by small RCT sample sizes and absent long-term data [s5, s7], while the community (score 68) reports predominantly positive experiences — particularly for hormonal acne — that exceed the current scientific evidence base [c1, c2]. The discrepancy reflects the difference between clinically validated endpoints and subjectively perceived symptom improvements.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
DIM is a bioactive metabolite from cruciferous vegetables that modulates CYP1A1/1A2 enzymes, shifting estrogen metabolism toward weaker 2-hydroxy metabolites. It additionally inhibits aromatase and influences androgen receptor signaling, providing a mechanistic rationale for use in hormone-dependent conditions and cancer prevention. Clinical evidence remains limited, with most data derived from in vitro and animal studies. With a moderate benefit-risk profile (benefit 3/5, risk 2/5), therapeutic efficacy in humans is not yet sufficiently established.
Description
DIM is a phytochemical from cruciferous vegetables that favorably influences estrogen metabolism and is being investigated in hormone-dependent conditions, acne, and potential cancer prevention [s1, s2].
Diindolylmethane (DIM) is formed during the digestive processing of indole-3-carbinol (I3C), a compound naturally occurring in cruciferous vegetables (broccoli, Brussels sprouts, cabbage). In gastric acid, I3C condenses to DIM, which is considered the more bioactive and stable compound [s1, s2]. Approximately 60% of ingested I3C is converted to DIM [s2]. DIM influences estrogen metabolism by promoting formation of the more favorable metabolite 2-hydroxyestrone while inhibiting the less favorable 16-alpha-hydroxyestrone [s3, s4]. This shift is associated with a potentially beneficial effect on breast cancer risk and other hormone-dependent conditions [s4, s5]. Clinical studies have investigated DIM in breast and prostate cancer, cervical intraepithelial neoplasia (CIN), HPV infection, and prostatic dysplasia [s5, s6]. Results are encouraging but not yet conclusively assessable due to small sample sizes and heterogeneous study designs [s5]. DIM has poor bioavailability in crystalline form; specialized formulations such as BioResponse-DIM increase absorption by approximately 50% [s7, s8]. The substance is also used in the bodybuilding community and for hormonal acne [c1, c2]. Data on long-term safety with continuous use remain limited [s9].
Legal Status (DE)
In Germany, Austria, and Switzerland, DIM is commercially available as a food supplement (NEM) and must be notified prior to placing on the market but does not require regulatory approval. In the United Kingdom, DIM is classified as a novel food and is not marketable without specific authorization. In the EU, the novel food status of DIM has not been conclusively determined; distribution in the DACH region currently proceeds under food supplement legislation.
Mechanism of Action
DIM acts through several complementary mechanisms: 1. Estrogen metabolism: DIM modulates cytochrome P450 enzymes (particularly CYP1A1, CYP1A2), favoring 2-hydroxylation of estradiol. The resulting 2-hydroxyestrone is considered less estrogenic than 16-alpha-hydroxyestrone [s3, s4]. 2. Aromatase inhibition: DIM can partially inhibit aromatase activity (conversion of androgens to estrogens), although it is not a classical aromatase inhibitor [s3]. 3. Androgen receptor modulation: Antagonistic effects at androgen receptors have been observed at high doses, which may be clinically relevant for male users [c3]. 4. Cannabinoid receptor agonism: DIM has been identified as a mild agonist at CB1 and CB2 cannabinoid receptors with low binding affinity [s1]. 5. Antiproliferative and anti-inflammatory effects: DIM inhibits NF-κB signaling pathways, regulates apoptosis genes, and inhibits cellular proliferation markers in various cancer cell lines [s5, s6]. 6. Antiviral activity: In cell studies, DIM demonstrated efficacy against HPV-associated dysplasias [s5]. The bioavailability of crystalline DIM is low; absorbed DIM is not metabolized to plasma metabolites following oral ingestion, so biological effects are mediated exclusively by the parent compound [s7, s8].
Dosing
Hormonelle Akne (Frauen)
- Dose
- 100–200 mg DIM daily (bioavailability-optimized formulation)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 8–12 Wochen, danach Evaluierung
- Timing
- With a meal
- With food
- empfohlen
Östrogenmetabolismus / Hormonbalance
- Dose
- 150–300 mg DIM daily (BioResponse-DIM or equivalent formulation)
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- 12 Wochen
- Timing
- With a fat-containing meal for better absorption
- With food
- empfohlen
Prostatadysplasie / zervikale Neoplasie (klinische Studiendosen)
- Dose
- 2 mg/kg body weight daily (equivalent to approx. 150–300 mg at 75 kg)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 6–12 Monate (nur unter ärztlicher Aufsicht)
- Timing
- With a meal
- With food
- empfohlen
Klinisch-therapeutische Dosierung (Forschungsdosen)
- Dose
- 500–1000 mg daily (in controlled studies only)
- Frequency
- aufgeteilt auf 2–3 Dosen
- Route
- oral
- Duration
- Studienprotokoll-abhängig
- Timing
- With meals
- With food
- empfohlen
No upper limit has been established by regulatory authorities. Clinical studies have used up to 1000 mg/day without serious adverse effects; however, long-term safety data are lacking. Typical supplement doses range from 100–300 mg/day [s5, s9].
Crystalline DIM has significantly lower bioavailability than specialized formulations (e.g., BioResponse-DIM with phosphatidylcholine and silica). When using generic products, the effective dose may be lower than stated [s7, s8].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Magenkrämpfe, Durchfall) Most frequently reported adverse effect at higher doses in clinical studies; generally mild and reversible [s9, s5]. | gelegentlich | leicht |
| Kopfschmerzen Reported in controlled safety studies; mechanism unclear, possibly hormonally mediated [s9]. | gelegentlich | leicht |
| Dunkelfärbung des Urins Due to excretion of DIM metabolites; not clinically significant [s9]. | gelegentlich | leicht |
| Erstreaktion: vorübergehende Verschlechterung der Akne oder Hautbild Reported by community users; likely due to initial hormonal fluctuations [c1, c2]. | gelegentlich | leicht |
| Stimmungsschwankungen, Reizbarkeit Reported in isolated cases; possibly due to a shift in estrogen metabolism [c1, c3]. | selten | leicht |
| Gynäkomastie oder hormonelle Dysbalance (bei Männern) Possibly via androgen receptor antagonism at high doses; case reports in the biohacking community [c3]. | selten | moderat |
| Menstruationsunregelmäßigkeiten Theoretically possible due to the effect on estrogen metabolism; reported in individual cases [s9]. | selten | moderat |
| Theoretische hormonelle Langzeiteffekte bei dauerhafter Einnahme Long-term safety data are lacking; caution is warranted due to the influence on sex hormones [s9]. | theoretisch | moderat |
Contraindications
No safety data available; hormonally active substance with unknown fetal risk [s9].
DIM significantly affects estrogen metabolism; uncontrolled use in existing hormone-dependent tumors is not justifiable [s5, s9].
Additive or competitive effects on estrogen metabolism possible; clinical relevance insufficiently studied [s4, s9].
DIM is hepatically metabolized via CYP enzymes; altered pharmacokinetics possible in impaired hepatic function [s7].
No safety data for this age group; hormonal effects during developmental stages are unpredictable [s9].
Interactions
Synergistic
Co-occurrence in cruciferous vegetables; possibly additive antioxidant and anticarcinogenic effect [s2].
DIM is the active metabolite of I3C; supplementation with I3C leads to endogenous DIM formation [s1, s2].
DIM supports the conversion of estrogen to favorable metabolites (2-hydroxylation pathway), while Calcium-D-Glucarate promotes excretion of these metabolites by inhibiting beta-glucuronidase. The combination demonstrates a synergistic effect on hormonal balance and hepatic detoxification.
DHEA and DIM may jointly support hormonal balance – DHEA increases precursor hormone availability, while DIM reduces the conversion of testosterone to estrogen via aromatase inhibition. The result is a more favorable testosterone-to-estrogen balance.
Ashwagandha lowers cortisol and supports testosterone levels, while DIM regulates estrogen metabolism. Together, they may promote a more comprehensive hormonal balance in both men and women.
DIM and curcumin act complementarily on inflammatory processes and aromatase inhibition. Both substances may jointly exert beneficial effects on estrogen metabolism and inflammatory signaling pathways.
DIM and sulforaphane both derive from cruciferous vegetables and jointly support hepatic detoxification and estrogen metabolism. The combination may exhibit additive effects on hormonal balance.
Caution
DIM affects the same estrogen metabolism pathway; additive anti-estrogenic effects or interactions possible [s4, s5].
DIM induces CYP1A2 enzymes; increased metabolism of CYP1A2 substrates possible, potentially reducing their efficacy [s7].
DIM may inhibit CYP3A4; altered plasma levels of CYP3A4 substrates (e.g., certain statins, immunosuppressants) possible [s7].
DIM may theoretically affect the efficacy of oral contraceptives through altered estrogen metabolism; interaction not well established clinically [s3, s9].
DIM at high doses can significantly affect estrogen metabolism, thereby altering the efficacy of hormone replacement therapy. Concomitant use should be medically supervised.
Studies
Tier A — High Evidence
Outcome: Cancer prevention, estrogen metabolism, cervical dysplasia, prostatic dysplasia
Effect Size: Significant improvement in 2-OHE1/16-OHE1 ratio; partial regression of cervical CIN; evidence of activity in castration-resistant prostate cancer
Outcome: Reversal of prostatic intraepithelial neoplasia (PIN)
Effect Size: Statistically significant PIN regression in the DIM group vs. placebo
Outcome: Urinary estrogen metabolites (2-OHE1, 16-OHE1)
Effect Size: Significant increase in 2-OHE1/16-OHE1 ratio under DIM
Tier B — Moderate Evidence
Outcome: Aromatase activity and estrogen metabolites in postmenopausal women
Effect Size: Change in urinary estrogen metabolite profile; moderate effects
Outcome: Safety, tolerability, pharmacokinetics
Effect Size: Well tolerated up to 300 mg/day; no serious adverse events
Tier C — Low Evidence
Outcome: Bioavailability of various DIM formulations
Effect Size: BioResponse-DIM showed approximately 50% higher bioavailability than crystalline DIM
Outcome: Plasma concentrations of DIM after oral administration of the BioResponse formulation
Effect Size: Detectable plasma levels following intake of the formulated variant; crystalline DIM poorly absorbed
Community Evidence
Top reported benefits
- Improvement of hormonal acne (particularly in women)
- Reduction of water retention
- Improved mood and hormonal balance
- Reduction of estrogen dominance symptoms
Top reported issues
- Initial reaction with transient acne worsening
- Mood swings at higher doses
- Unclear effect in male users (androgen receptor concerns)
- Menstrual irregularities in isolated cases
Male bodybuilders extensively discuss the risk of androgen receptor blockade at doses above 200 mg/day [c3]. Several users report that efficacy is highly dependent on product quality and formulation — generic DIM products are rated as less effective than BioResponse-DIM-based products [c1, c4]. One female user reported persistent menstrual cycle disturbances following several months of use [c2].
Scientific Sources
- Unveiling the Multifaceted Pharmacological Actions of Indole-3-Carbinol and Diindolylmethane: A Comprehensive Review
Kaur N, Singh R, Dar Z, et al. (2025). PMC (PubMed Central)BPMID:40094833 - Sulforaphane, 3,3′-Diindolylmethane and Indole-3-Carbinol: A Review of Clinical Use and Efficacy
Stephenson J, Banerjee A, Edwards K, et al. (2022). Nutritional Medicine InstituteBLink - 3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways
Shoaib S, Ansari MA, Bhatt R, et al. (2023). PMC (PubMed Central)BLink - 3,3′-Diindolylmethane Modulates Estrogen Metabolism in Healthy Men and Women
Zeligs MA, Sepkovic DW, Manrique C, et al. (2011). PMC (PubMed Central)BLink - The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolism: A systematic review and meta-analysis
Thomson CA, Ho E, Strom MB, et al. (2023). PMC (PubMed Central)APMID:36757700 - Anti-Cancer and Other Biological Effects of a Dietary Compound 3,3′-Diindolylmethane Supplementation: A Systematic Review of Human Clinical Trials
Dalessandri KM, Firestone GL, Fitch MD, et al. (2020). Nutrition and Dietary SupplementsADOI - First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
Paltsev M, Kiselev V, Drukh V, et al. (2016). EPMA JournalADOI - Comparative preclinical pharmacokinetics study of 3,3′-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon?
Anderton MJ, Manson MM, Verschoyle R, et al. (2004). PMC (PubMed Central)CPMID:15155555 - Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3,3′-Diindolylmethane in Healthy Subjects
Reed GA, Sunega JM, Sullivan DK, et al. (2008). Cancer Epidemiology, Biomarkers & Prevention / PMCBLink - A Controlled Safety Study of Diindolylmethane in Participants with CIN2/3
Del Priore G, Gudipudi DK, Montemarano N, et al. (2010). PMC (PubMed Central)ALink
Community Sources
Storage
Unopened
Store in a dry, cool place at room temperature (15–25 °C), protected from direct light and moisture.
Opened
Keep container tightly closed; use within the stated expiry date.
Notes
Specialized formulations (e.g., with phosphatidylcholine) may be more sensitive to heat and moisture than crystalline DIM. Follow manufacturer instructions [s8].